19:34 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Mouse studies identified a peptide-based inhibitor of the LTBR-TRAF3 interaction that could help treat contact hypersensitivity. The fusion consists of a 28-amino acid, cell-penetrating peptide from the N-terminus of...
14:16 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Scleroderma Mouse and cell cultures studies suggest agonizing LTBR in adipose-derived mesenchymal stromal cell (ADSC) grafts could help treat skin fibrosis in scleroderma. ADSC numbers were lower in the dermal white adipose tissue (WAT)...
07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL) Lymphotoxin-a (LTa); lymphotoxin-b receptor (LTBR); chemokine CXC motif ligand 13 (CXCL13); CXC chemokine receptor 5 (CXCR5) Mouse studies suggesting inhibiting LTa-LTBR...
07:00 , Mar 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HBV Lymphotoxin-b receptor (LTBR) In vitro studies suggest activating LTBR could help treat HBV infection. HBV forms a stable, nuclear covalently closed circular DNA...
07:00 , Aug 29, 2011 |  BioCentury  |  Strategy

R&D reboot

Charged with a mandate to reinvigorate and streamline R&D and ensure investors see value for money spent, Biogen Idec Inc. 's new management has pruned the pipeline and instilled a new culture of intelligent risk...
07:00 , May 5, 2011 |  BC Innovations  |  Cover Story

LIGHTs out for asthma

Two years after Kyowa Hakko Kirin Co. Ltd....
07:00 , Apr 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Tumor necrosis factor ligand superfamily member 14 (TNFSF14; LIGHT; CD258) Mouse studies suggest that inhibiting LIGHT could help treat asthma...
07:00 , Apr 8, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Lymphotoxin-b receptor (LTBR) In vitro and mouse studies suggest that upregulating LTBR signaling in epithelial cells could help treat mucosal bacterial infection....
07:00 , Mar 25, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Lymphotoxin-b (LTb); LTb receptor (LTBR) A study in mice and in patient samples suggests that blocking LTb expression in B cells could help...
07:00 , Mar 25, 2010 |  BC Innovations  |  Cover Story

A B cell burden in prostate cancer

Although castration therapies such as androgen ablation are standard prostate cancer treatments, many patients develop resistance in 12-18 months. 1 Now, researchers from the University of California, San Diego and Scripps Florida have found that...